1. 1. Li L, Vlisides PE. Ketamine: 50 Years of Modulating the Mind. Front Hum Neurosci. 2016;10:612.
2. F. Aroni, N. Iacovidou, I. Dontas, C. Pourzitaki, and T. Xanthos, “Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug,” Journal of Clinical Pharmacology, vol. 49, no. 8, pp. 957–964, 2009.
3. J. Persson, “Ketamine in pain management,” CNS Neuroscience & Therapeutics, vol. 19, no. 6, pp. 396–402, 2013.
4. Liao Y, Tang YL, Hao W. Ketamine and international regulations. Am J Drug Alcohol Abuse. 2017 Sep;43(5):495-504.
5. Cartwright PD, Pingel SM. Midazolam and diazepam in ketamine anaesthesia. Anaesthesia. 1984 May;39(5):439-42.
6. Andrade C. Ketamine for Depression, 1: Clinical Summary of Issues Related to Efficacy, Adverse Effects, and Mechanism of Action. J Clin Psychiatry. 2017 Apr;78(4):e415-e419.
7. M. Naughton, G. Clarke, O. F. O'Leary, J. F. Cryan, and T. G. Dinan, “A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action,” Journal of Affective Disorders, vol. 156, pp. 24–35, 2014.
8. P. Azari, D. R. Lindsay, D. Briones, C. Clarke, T. Buchheit, and S. Pyati, “Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review,” CNS Drugs, vol. 26, no. 3, pp. 215–228, 2012.
9. R. F. Bell, C. Eccleston, and E. A. Kalso, “Ketamine as an adjuvant to opioids for cancer pain,” The Cochrane Database of Systematic Reviews, no. 11, Article ID CD003351, 2012.
10. J. H. Krystal, S. Madonick, E. Perry et al., “Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism,” Neuropsychopharmacology, vol. 31, no. 8, pp. 1793–1800, 2006.
11. E. Krupitsky, A. Burakov, T. Romanova, I. Dunaevsky, R. Strassman, and A. Grinenko, “Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up,” Journal of Substance Abuse Treatment, vol. 23, no. 4, pp. 273–283, 2002.
12. K. R. Jat and D. Chawla, “Ketamine for management of acute exacerbations of asthma in children,” The Cochrane Database of Systematic Reviews, vol. 11, Article ID CD009293, 2012.
13. K. R. Jat, C. Azad, and V. Guglani, “Use of ketamine for refractory wheezing in an infant,” Indian Pediatrics, vol. 49, no. 7, pp. 587–588, 2012.
14. M. Wang, Q. Wang, Y. Y. Yu, and W. S. Wang, “An effective dose of ketamine for eliminating pain during injection of propofol: a dose response study,” Annales Francaises d'Anesthesie et de Reanimation, vol. 32, no. 9, pp. e103–e106, 2013.
15. N. Katalinic, R. Lai, A. Somogyi, P. B. Mitchell, P. Glue, and C. K. Loo, “Ketamine as a new treatment for depression: a review of its efficacy and adverse effects,” The Australian and New Zealand Journal of Psychiatry, vol. 47, no. 8, pp. 710–727, 2013.
16. Passie T, Adams HA, Logemann F, Brandt SD, Wiese B, Karst M. Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers. European Neuropsychopharmacology. 2021 Mar 1;44:92-104.
17. Domino EF. Neuronal mechanisms of ketamine-induced anesthesia. International journal of neuropharmacology. 1968 Nov 1;7(6):557-73.
18. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther. 1992 Mar;260(3):1209-13.
19. Ben-Shlomo I, Rosenbaum A, Hadash O, Katz Y. Intravenous midazolam significantly enhances the lethal effect of thiopental but not that of ketamine in mice. Pharmacol Res. 2001 Dec;44(6):509-12.
20. Hansen G, Jensen SB, Chandresh L, Hilden T. The psychotropic effect of ketamine. J Psychoactive Drugs. 1988 Oct-Dec;20(4):419-25.
21. Deer TR, Pope JE, Hayek SM, Lamer TJ, Veizi IE, Erdek M, Wallace MS, Grider JS, Levy RM, Prager J, Rosen SM, Saulino M, Yaksh TL, De Andrés JA, Abejon Gonzalez D, Vesper J, Schu S, Simpson B, Mekhail N. The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks. Neuromodulation. 2017 Feb;20(2):155-176.
22. C. J. A. Morgan and H. V. Curran, “Ketamine use: a review,” Addiction, vol. 107, no. 1, pp. 27–38, 2012.
23. R. J. Strayer and L. S. Nelson, “Adverse events associated with ketamine for procedural sedation in adults,” The American journal of emergency medicine, vol. 26, no. 9, pp. 985–1028, 2008.
24. P. Azari, D. R. Lindsay, D. Briones, C. Clarke, T. Buchheit, and S. Pyati, “Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review,” CNS Drugs, vol. 26, no. 3, pp. 215–228, 2012.
25. N. Katalinic, R. Lai, A. Somogyi, P. B. Mitchell, P. Glue, and C. K. Loo, “Ketamine as a new treatment for depression: a review of its efficacy and adverse effects,” The Australian and New Zealand Journal of Psychiatry, vol. 47, no. 8, pp. 710–727, 2013.
26. S. Himmelseher and M. E. Durieux, “Ketamine for perioperative pain management,” Anesthesiology, vol. 102, no. 1, pp. 211–220, 2005.
27. H. S. Smith, “Ketamine-induced urologic insult (KIUI),” Pain Physician, vol. 13, no. 6, pp. E343–E346, 2010.
28. A. C. Scallet, L. C. Schmued, W. Slikker Jr. et al., “Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons,” Toxicological Sciences, vol. 81, no. 2, pp. 364–370, 2004.
29. V. Jevtovic-Todorovic, D. F. Wozniak, N. D. Benshoff, and J. W. Olney, “A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide,” Brain Research, vol. 895, no. 1-2, pp. 264–267, 2001.
30. C. Dong and K. J. S. Anand, “Developmental neurotoxicity of ketamine in pediatric clinical use,” Toxicology Letters, vol. 220, no. 1, pp. 53–60, 2013.
31. M. G. Paule, M. Li, R. R. Allen et al., “Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys,” Neurotoxicology and Teratology, vol. 33, no. 2, pp. 220–230, 2011.
32. L. C. Chang, S. R. Raty, J. Ortiz, N. S. Bailard, and S. J. Mathew, “The emerging use of ketamine for anesthesia and sedation in traumatic brain injuries,” CNS Neuroscience & Therapeutics, vol. 19, no. 6, pp. 390–395, 2013.
33. K. Michalczyk, J. E. Sullivan, and J. W. Berkenbosch, “Pretreatment with midazolam blunts the rise in intracranial pressure associated with ketamine sedation for lumbar puncture in children,” Pediatric Critical Care Medicine, vol. 14, no. 3, pp. e149–e155, 2013.
34. N. Gaspard, B. Foreman, L. M. Judd et al., “Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study,” Epilepsia, vol. 54, no. 8, pp. 1498–1503, 2013.
35. E. B. Perry Jr., J. A. Cramer, H.-S. Cho et al., “Psychiatric safety of ketamine in psychopharmacology research,” Psychopharmacology, vol. 192, no. 2, pp. 253–260, 2007.
36. Demaria S, Weinkauf JL. Cocaine and the club drugs. Int Anesthesiol Clin. 2011 Winter;49(1):79-101.
37. Tobias JD, Leder M. Procedural sedation: A review of sedative agents, monitoring, and management of complications. Saudi J Anaesth. 2011 Oct;5(4):395-410.
38. Bokor G, Anderson PD. Ketamine: an update on its abuse. J Pharm Pract. 2014 Dec;27(6):582-6.
39. Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, Viscusi ER, Narouze S, Davis FN, Ritchie EC, Lubenow TR, Hooten WM. Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018 Jul;43(5):521-546.
40. Trivedi S, Kumar R, Tripathi AK, Mehta RK. A Comparative Study of Dexmedetomidine and Midazolam in Reducing Delirium Caused by Ketamine. J Clin Diagn Res. 2016 Aug;10(8):UC01-4.
41. Sollazzi L, Modesti C, Vitale F, Sacco T, Ciocchetti P, Idra AS, Tacchino RM, Perilli V. Preinductive use of clonidine and ketamine improves recovery and reduces postoperative pain after bariatric surgery. Surg Obes Relat Dis. 2009 Jan-Feb;5(1):67-71.